Want to see TSE:INNO full AI Analyst Report?
Total Valuation
InnoCan Pharma has a market cap or net worth of C$8.55M. The enterprise value is C$8.16M.
Market CapC$8.55M
Enterprise ValueC$8.16M
Share Statistics
InnoCan Pharma has 4,498,772 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,498,772
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCan Pharma’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is 54.92%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)54.92%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee2.42M
Profits Per Employee-31.00K
Employee Count11
Asset Turnover2.53
Inventory Turnover1.23
Valuation Ratios
The current PE Ratio of InnoCan Pharma is ―. InnoCan Pharma’s PEG ratio is 0.48.
PE Ratio―
PS Ratio0.82
PB Ratio3.90
Price to FCF45.60
Price to Operating Cash Flow-4.02
PEG Ratio0.48
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 26.61M and earned -1.12M in profits. Earnings per share was -0.25.
Revenue26.61M
Gross Profit23.93M
Operating Income-1.25M
Pretax Income85.00K
Net Income-1.12M
EBITDA130.00K
Earnings Per Share (EPS)-0.25
Cash Flow
In the last 12 months, operating cash flow was -1.52M and capital expenditures -19.02K, giving a free cash flow of -1.54M billion.
Operating Cash Flow-1.52M
Free Cash Flow-1.54M
Free Cash Flow per Share-0.34
Dividends & Yields
InnoCan Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.71
52-Week Price Change-89.73%
50-Day Moving Average2.15
200-Day Moving Average4.68
Relative Strength Index (RSI)36.60
Average Volume (3m)1.00K
Important Dates
InnoCan Pharma upcoming earnings date is Dec 2, 2026, Before Open (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateDec 2, 2026
Ex-Dividend Date―
Financial Position
InnoCan Pharma as a current ratio of 7.70, with Debt / Equity ratio of 34.65%
Current Ratio7.70
Quick Ratio6.09
Debt to Market Cap0.04
Net Debt to EBITDA-44.28
Interest Coverage Ratio-418.33
Taxes
In the past 12 months, InnoCan Pharma has paid 426.00K in taxes.
Income Tax426.00K
Effective Tax Rate5.01
Enterprise Valuation
InnoCan Pharma EV to EBITDA ratio is 123.74, with an EV/FCF ratio of 33.58.
EV to Sales0.60
EV to EBITDA123.74
EV to Free Cash Flow33.58
EV to Operating Cash Flow32.50
Balance Sheet
InnoCan Pharma has C$6.44M in cash and marketable securities with C$1.66M in debt, giving a net cash position of C$4.78M billion.
Cash & Marketable SecuritiesC$6.44M
Total DebtC$1.66M
Net CashC$4.78M
Net Cash Per ShareC$1.06
Tangible Book Value Per ShareC$1.84
Margins
Gross margin is 90.45%, with operating margin of -4.72%, and net profit margin of -4.22%.
Gross Margin90.45%
Operating Margin-4.72%
Pretax Margin0.32%
Net Profit Margin-4.22%
EBITDA Margin0.49%
EBIT Margin0.33%
Analyst Forecast
The average price target for InnoCan Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-19.20%
EPS Growth Forecast42.54%